



Pressrelease
4 January 2007

New Major Shareholder in Tripep

Verrazano Ltd, (owned by the Verrezano Trust), a company represented by Mr Thomas Lynch, the non-executive chairman and major shareholder of the London Stock Exchange and NASDAQ listed biotech company Amarin Corporation, has today announced that they acquired the shareholding previously owned by Dormant Properties. After consulting the major shareholders representing more than 50% of the shares, Anders Vahlne, acting chairman of the board of Tripep, is pleased to announce that Thomas Lynch has accepted the candidature as Chairman of the Board. It is proposed that Thomas Lynch be elected at the Company's Extraordinary Shareholders Meeting planned for later this month.

From 1993 to 2004 Mr. Lynch worked in a variety of capacities in Europe's largest biotech company, Elan Corporation Plc., from the position as chief financial officer and executive vice-president; and subsequently as vice chairman Mr. Lynch led Elan's transformation from a drug delivery company to a biotechnology company through a series of corporate and product acquisitions and joint ventures.

Mr. Lynch also serves as a board member of Icon plc (a clinical research company); IDA Ireland (an agency of the Government of Ireland responsible for inward investment); Profectus Inc., (a privately held US biotechnology company); the Royal Opera House in London and serves as chairman of the Queen's University of Belfast Foundation and HRH The Prince of Wales's Foundation for Integrated Health.

Prof Anders Vahlne, acting Chairman of Tripep: "I am very pleased that Mr. Lynch has agreed to join the Board of Tripep and invest in the Company. He brings an enormous wealth of experience from the Biotech Industry to Tripep. Moreover, his broad international network will be invaluable to the Company when initiating discussions with commercial partners as we enter into clinical trials with both ChronVac-C[®], Tripep's candidate drug for the treatment of chronic hepatitis C virus infections and ChronSeal, our recently acquired treatment for chronic leg ulcers."

"I am very pleased to accept the nomination as Chairman of Tripep AB. I have enormous respect and admiration for the quality of medical and scientific research in Sweden and very much look forward to working with the management to build our research and development of medicines for immunological and virological diseases, an area of significant unmet medical need", says Mr Thomas Lynch.

For more information, please contact:

Anders Vahlne, Head of Research and acting Chairman of the Board, Tripep AB
Tel: +46 8 5858 1313, mobile phone: +46 709 28 05 28
E-mail: anders.vahlne@ki.se

Jan Nilsson, CEO, Tripep AB
Tel: +46 8 449 84 80, mobile phone: +46 70 466 31 63
E-mail: jan.nilsson@tripep.se

Tripep AB is a Swedish biotechnology research company that develops and commercialises candidate drugs based on patented technologies. Its main focuses are:

- *clinical development of ChronSeal, a wound healing project based on HGF (Hepatocyte Growth Factor),*
- *clinical development of ChronVac-C[®], a therapeutic vaccine for Hepatitis C*
- *preclinical research focusing on the development of therapeutic and prophylactic vaccines against HIV and Hepatitis C,*
- *the RAS[®] technology platform*

For more details of Tripep's technologies, please refer to the company's web site at www.tripep.se